Article information
Abstract
Objective
Determine the prevalence of metabolic abnormalities (MA) and estimate the 10-year risk for cardiovascular disease (CVD) among Latin American HIV-infected patients receiving highly active anti-retroviral therapy (HAART).
MethodsA cohort study to evaluate MA and treatment practices to reduce CVD has been conducted in seven Latin American countries. Adult HIV-infected patients with at least one month of HAART were enrolled. Baseline data are presented in this analysis.
ResultsA total of 4,010 patients were enrolled. Mean age (SD) was 41.9 (10) years; median duration of HAART was 35 (IQR: 10-51) months, 44% received protease inhibitors. The prevalence of dyslipidemia and metabolic syndrome was 80.2% and 20.2%, respectively. The overall 10-year risk of CVD, as measured by the Framingham risk score (FRF), was 10.4 (24.7). Longer exposure to HAART was documented in patients with dyslipidemia, metabolic syndrome and type 2 diabetes mellitus. The FRF score increased with duration of HAART. Male patients had more dyslipidemia, high blood pressure, smoking habit and higher 10-year CVD than females.
ConclusionsTraditional risk factors for CVD are prevalent in this setting leading to intermediate 10-year risk of CVD. Modification of these risk factors through education and intervention programs are needed to reduce CVD.
Keywords:
HAART
HIV
metabolic parameters
cardiovascular risk factors
metabolic syndrome
dyslipidemia
Full text is only aviable in PDF
References
[1.]
F.J. Palella, K.M. Delaney, A.C. Moorman, et al.
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators.
N Eng J Med, 338 (1998), pp. 853-860
[2.]
A. Carr, K. Samaras, S. Burton, J. Freund, D.J. Chisholm, D.A. Cooper.
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors.
AIDS, 12 (1998), pp. F51-F58
[3.]
S. Grinspoon, A. Carr.
Cardiovascular risk and body-fay abnormalities in HIV-infected adults.
N Eng J Med, 352 (2005), pp. 48-62
[4.]
V.A. Triant, H. Lee, C. Hadigan, S.K. Grinspoon.
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease.
J Clin Endocrinol Metab, 92 (2007), pp. 2506-2512
[5.]
J.S. Currier, A. Taylor, F. Boyd, et al.
Coronary heart disease in HIV-infected individuals.
J Acquir Immune Defic Syndr, 33 (2003), pp. 506-512
[6.]
N. Obel, H.F. Thomsen, G. Kronborg, et al.
Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study.
Clin Infect Dis, 44 (2007), pp. 1625-1631
[7.]
U.H. Iloeje, Y. Yuan, G. L’italien, et al.
Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.
HIV Med, 6 (2005), pp. 37-44
[8.]
M. Mary-Krause, L. Cotte, A. Simon, M. Partisani, D. Costagliola.
Clinical Epidemiology Group From the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.
AIDS, 17 (2003), pp. 2479-2486
[9.]
J.S. Currier, J.E. Lundgren, A.C. Carr, et al.
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.
Circulation, 118 (2008), pp. e29-e35
[10.]
AIDS epidemic update 2007. UNAIDS/07.27E/JC1322E. December 2007.
[11.]
S.M. Grundy, H.B. Brewer Jr, J.I. Cleeman, S.C. Smith Jr, C. Lenfant.
American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.
Circulation, 109 (2004), pp. 433-438
[12.]
G.V. De Socio, L. Martinelli, S. Morosi, et al.
Is estimated cardiovascular risk higher in HIV-infected patients than in the general population?.
Scand J Infect Dis, 39 (2007), pp. 805-812
[13.]
G.V.L. De Socio, G. Parruti, T. Quirino, et al.
Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study.
J Infect, (2008),
[14.]
J. Santos, R. Palacios, M. González, J. Ruiz, M. Márquez.
Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Nétar Study).
Int J STD AIDS, 16 (2005), pp. 677-680
[15.]
B.M. Bergersen, L. Sandvik, J.N. Bruun, S. Tonstad.
Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects.
Eur J Clin Microbiol Infect Dis, 23 (2004), pp. 625-630
[16.]
R.C. Kaplan, L.A. Kingsley, A.R. Sharrett, et al.
Ten-year predicted coronary heart disease risk in HIV-infected men and women.
Clin Infect Dis, 45 (2007), pp. 1074-1081
[17.]
H. Schargrodsky, R. Hernández-Hernández, B.M. Champagne, et al.
CARMELA: assessment of cardiovascular risk in seven Latin American cities.
Am J Med, 121 (2008), pp. 58-65
[18.]
M.G. Law, N. Friis-Møller, W.M. El-Sadr, et al.
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.
HIV Med, 7 (2006), pp. 218-230
[19.]
N. Friis-Møller, C.A. Sabin, R. Weber, et al.
Combination antiretroviral therapy and the risk of myocardial infarction.
N Eng J Med, 349 (2003), pp. 1993-2003
[20.]
N. Friis-Møller, P. Reiss, C.A. Sabin, et al.
Class of antiretroviral drugs and the risk of myocardial infarction.
N Eng J Med, 356 (2007), pp. 1723-1735
[21.]
N. Friis-Møller, R. Weber, P. Reiss, et al.
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
AIDS, 17 (2003), pp. 179-183
[22.]
M. Savès, G. Chêne, P. Ducimetière, et al.
Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.
Clin Infect Dis, 37 (2003), pp. 292-298
[23.]
E.R. Gritz, D.J. Vidrine, A.B. Lazev, B.C. Amick 3rd, R.C. Arduino.
Smoking behavior in a low-income multiethnic HIV/AIDS population.
Nicotine Tob Res, 6 (2004), pp. 71-77
[24.]
K. Samaras, H. Wand, M. Law, S. Emery, D. Cooper, A. Carr.
Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia.
Diabetes Care, 30 (2007), pp. 113-119
[25.]
P. Bonfanti, C. Giannattasio, E. Ricci, et al.
HIV and metabolic syndrome: a comparison with the general population.
J Acquir Immune Defic Syndr, 45 (2007), pp. 426-431
[26.]
K. Mondy, E.T. Overton, J. Grubb, S. Tong, W. Seyfried, W. Powderly, K. Yarasheski.
Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population.
Clin Infect Dis, 44 (2007), pp. 726-734
[27.]
K. Samaras.
Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.
J Antimicrob Chemother, 61 (2008), pp. 238-245
[28.]
T. Neumann, T. Woiwod, A. Neumann, et al.
Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients, Part III: gender differences.
Eur J Med Res, 27 (2004), pp. 55-60
